Tag: Multiple Myeloma

A German case report describes rapid deep response to ciltacabtagene autoleucel as a second BCMA-directed CAR T-cell therapy after mezigdomide-based ...

A single-cell atlas of 341 multiple myeloma patients identifies five malignant transcriptional archetypes and an orthogonal proliferative program, enabling improved ...

A new commentary argues that exceptional long-term responses to melflufen-dexamethasone in myeloma case reports should not override subgroup trial evidence ...

A combined blood-based inflammation and nutrition score strongly predicted survival outcomes in newly diagnosed multiple myeloma patients, improving risk stratification ...

A new study maps distinct inflammatory cytokine and PACAP-38 signatures in multiple myeloma, linking elevated IL-10 and other markers to ...

Multiple myeloma has long challenged researchers because the disease is not driven only by uncontrolled growth. Its malignant plasma cells ...

Multiple myeloma is entering an era of unprecedented therapeutic choice—and equally unprecedented uncertainty. A new clinical perspective by C.R. Tan ...

Rochester, Minn. — A major U.S.-led cooperative group clinical trial coordinated by Mayo Clinic researchers has found that extending maintenance ...

A landmark phase 3 trial in newly diagnosed multiple myeloma challenges a long-standing standard: indefinite lenalidomide maintenance. For patients who ...

Pomalidomide (POM) has emerged as a pivotal agent in the treatment landscape for multiple myeloma, a malignancy that significantly compromises ...